Patients with kidney cancer to pay only 10% of Nexava NHI price.

Published: 2007-03-30 06:58:00

Updated: 2007-03-30 06:58:00

The NHI reimbursement of Nexava, a new oral anti-kidney cancer drug (sorafenib) and first in its kind in the world, has been approved by the MOHW. Now, the patient may pay only 10% of the drug charges under the NHI coverage. The NHI price for Nexava 200mg tablet is 25,486 won/T taking effects fro...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK